OptiBiotix interesting big pharma with statin-free cholesterol pill
UK biotech OptiBiotix (LSE: OPTI) has been in talks with big pharma about a cholesterol pill believed to work as well as statins, but without the side effects, according to reports.
British newspaper The Times reported market interest in OptiBiotix’s research and its potential to avoid the need for statins, the side effects of which include headaches, joint pain and nosebleeds.
It comes after the company released further details this month on a 12-week double blind placebo controlled study of the tablet, which is made up of hundreds of millions of freeze-dried and compressed bacteria. The trial recruited 50 volunteers and was designed to establish safety, compliance, and the extent of the cholesterol lowering potential of OptiBiotix's Lactobacillus plantarum strain in mildly hypercholesterolemic adults.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze